26 reports

  • Respiratory Drugs Market Segmentation
  • Respiratory Drugs Market Characteristics

Development Of RMC-## Drug For Respiratory Diseases Treatment - The development of the RMC-## drug has enabled the blocking of the series of chain reactions that result in respiratory diseases such as asthma and COPD.

  • Respiratory Treatment
  • Market Size
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Respiratory Drugs Companies in China
  • Respiratory Drugs Sales Volume

Table ##: Economic Outlook Summary (Billion Yuan) Chart ##: Economic Outlook Summary (Billion Yuan) INTRODUCTION Chapter I The current market for respiratory drugs in China is growing rapidly.

  • Respiratory Treatment
  • China
  • Demand
  • AstraZeneca China Inc.
  • Zhongmei Shike Pharmaceutical Co., Ltd
  • Profiles of Respiratory Drugs Producers
  • Respiratory Drugs Markets in China

Throat preparations as one of the mainstream respiratory drugs have a large number of drug groups and a broad market.

  • Respiratory Treatment
  • China
  • Demand
  • Market Size
  • GlaxoSmithKline plc
  • Respiratory Drugs Market Overview
  • IV. RESPIRATORY DRUGS PRODUCTION AND DEMAND

Throat preparations as one of the mainstream respiratory drugs have a large number of drug groups and a broad market.

  • Respiratory Treatment
  • China
  • Demand
  • Market Size
  • Trade

Several respiratory drug companies are focused on evolving new respiratory drugs with the entry of biologics and biosimilars for promising options for respiratory disease management.

  • Respiratory Disease
  • Respiratory Treatment
  • Therapy
  • World
  • Market Size
  • Respiratory Drugs Import Volume and Market Share
  • Respiratory Drugs Sales Volume and Market Share

Other Respiratory Drugs mucus production.

  • Respiratory Treatment
  • China
  • Demand
  • Trade
  • Roche Group
  • Respiratory Drugs Sales Volume and Market Share
  • Respiratory Drugs Import Volume and Market Share

Chart ##: Respiratory Drugs Sales Volume and Market Share (Billion Yuan/ percent) Chapter IV ##.

  • Respiratory Treatment
  • China
  • Demand
  • GlaxoSmithKline plc
  • Roche Group
  • Respiratory Drugs
  • II. BUSINESS ENVIRONMENT

Chapter IV PRESCRIPTION DRUGS PRODUCTION AND DEMAND Table ##: Pain and Fever Relief Drugs Production and Demand (Million Yuan) Respiratory Drugs Respiratory disease is the term for diseases of the respiratory system.

  • Pharmaceutical
  • Prescription Drug
  • Respiratory Treatment
  • China
  • Demand
  • RESPIRATORY DRUGS MARKET IN EMEA
  • RESPIRATORY DRUGS MARKET IN AMERICAS

Low diagnosis rate is one of the major challenges for the global respiratory drugs market.

  • Respiratory Treatment
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • CIPLA

Product Categories: respiratory Therapy.

  • Respiratory Treatment
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici S.p.A.
  • Global respiratory drugs market
  • Global respiratory drugs market 2015-2020 ($ billions)

Develops drugs for the treatment of respiratory indications.

  • Respiratory Treatment
  • China
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • BOEHRINGER INGELHEIM

It undertakes the development of drugs for the treatment of respiratory disorders.

  • Respiratory Treatment
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • CHIESI'S COPD PORTFOLIO ASSESSMENT, 2017
  • 10.3.3 CHIESI

RESPIRATORY RESEARCH; ##(##): ##.

  • Respiratory Treatment
  • Australia
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Sunovion Pharmaceuticals Inc.
  • Key vendor analysis

Roflumilast (Daliresp) is one such drug available in the market.

  • Respiratory Treatment
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Strength
  • Vendor landscape

You can easily book an appointment with one online.

  • Respiratory Treatment
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • GLOBAL RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET

THE GROWING R& D ACTIVITIES TO DEVELOP DRUGS FOR PREVIOUSLY UNTAPPED MARKETS (ELDERLY POPULATION OF AGES MORE THAN ##) IS ONE OF THE BIGGEST UPCOMING TREND FOR THE HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) DRUGS MARKET.

  • Respiratory Treatment
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • 10. Market Segmentation by Therapeutic Application
  • 03.2 Product Offerings

Cardiovascular Drugs Respiratory Drugs Anti-cancer Drugs CNS Drugs The Others segment includes dermatology, genitourinary, gastrointestinal, and endocrine drugs.

  • Anti-Infective
  • Respiratory Treatment
  • Japan
  • Meiji Seika Pharma Co., Ltd.
  • Nipro Corporation

Advair is one of the major drugs in its portfolio, followed by Breo Ellipta and Serevent.

  • Respiratory Treatment
  • United States
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • FIVE MAJOR EU MARKETS PAYER INSIGHTS
  • IL-5 INHIBITORS

ONE PAYER ASSERTED THAT THE DRUG IS IN A NON-PREFERRED TIER BECAUSE IT IS NEW TO THE MARKET AND WILL BE REASSESSED DURING A BROAD RESPIRATORY REVIEW.

  • Asthma
  • Respiratory Treatment
  • Therapy
  • ESI Group
  • GlaxoSmithKline plc
  • INVION COMPLETES RIGHTS OFFERING OF SHARES FOR USD0.8 MILLION
  • INVION COMPLETES PRIVATE PLACEMENT OF SHARES FOR US$4.5 MILLION

Company Name Business Description GlobalData INVION ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH ##M DRUG DELIVERY SYSTEMS FOR INV## AND INV## Invion Enters Into Co-Development Agreement With ##M Drug Delivery Systems For INV## And INV## Invion Limited, a developer of

  • Respiratory Treatment
  • Australia
  • Company
  • M&A
  • Invion Limited

Chapter Eight: Other Drug Classifications Table ##-## U. S.

  • Respiratory Treatment
  • United States
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.

Cipla has a long history of blazing the trail in innovations in combination formulations and drug-device combinations in the respiratory therapy, and Niveoli™ is a painstaking result of these strengths.

  • Pulmonary Delivery
  • Respiratory Treatment
  • United States
  • Company Financials
  • Novartis AG

Hisamitsu offers OTC products namely, topical antifungal drugs, eye drops, quasi drugs, medical device, cosmetics, and health supplements as well as prescription products such as dermatologic drugs, CNS drugs, and respiratory system drugs to the

  • Incontinence Product
  • OTC
  • Pharmaceutical
  • Respiratory Treatment
  • Therapy
  • SEASONAL ALLERGIC RHINITIS - PIPELINE BY HISAMITSU PHARMACEUTICAL CO., INC., H1 2016

It offers products such as anti-inflammatory pain relieving patches, antifungal drugs, analgesic drugs, dermatological drugs, cosmetics, quasi drugs, respiratory system drugs and others.

  • Allergy Drug
  • OTC
  • Pharmaceutical
  • Respiratory Disease
  • Respiratory Treatment
  • PERENNIAL ALLERGIC RHINITIS - PIPELINE BY HISAMITSU PHARMACEUTICAL CO., INC., H1 2016

It offers products such as anti-inflammatory pain relieving patches, antifungal drugs, analgesic drugs, dermatological drugs, cosmetics, quasi drugs, respiratory system drugs and others.

  • Allergy Drug
  • Pharmaceutical
  • Respiratory Disease
  • Respiratory Treatment
  • Therapy

The company offers products such as anti-tuberculosis, cephalosporins (anti-infectives) and cardiovascular drugs (angiotensin-converting-enzyme (ACE)-inhibitors and cholesterol reducing agents) in the areas of diabetes, antiinflammatory and respiratory therapy.

  • Pharmaceutical
  • Respiratory Treatment
  • United States
  • Company
  • Dainippon Sumitomo Pharma Co., Ltd.